Key clinical point: Individuals with type 1 diabetes and a high body mass index gain the most benefit with the least risk from treatment with sodium-glucose cotransporter 2 inhibitors added to insulin therapy.
Major findings: Greater reductions in glycated hemoglobin and body weight were seen at higher BMI with sotagliflozin, and there was a trend for lower rates of diabetic ketoacidosis as BMI increased with dapagliflozin.
Study details: Two separate post hoc analyses of the inTandem 1 and 2 trials (n = 1,575) with sotagliflozin and DEPICT-1 and -2 trials (n = 548) with dapagliflozin used as add-on treatment to insulin in patients with type 1 diabetes; and the DEXA subanalysis looking at body weight and composition in adults with type 1 diabetes treated with sotagliflozin in the inTandem phase 3 studies (n = 243).
Disclosures: The inTandem studies were sponsored by Lexicon and Sanofi. Dr. Danne disclosed receiving research funding and serving as a consultant, advisory board or steering committee member, or speaker for various companies including Sanofi. Dr. Sawhney is an employee of and holds stoke in Lexicon. The DEPICT studies were sponsored by AstraZeneca. The lead author, Dr. Dandona, disclosed employment or consultancy services for multiple companies including AstraZeneca.
Danne T et al. EASD 2018, Oral Presentation 2; Dandona P et al. EASD 2019, ePoster 720; Sawhney S et al. EASD 2019, Orak Presentation 3.